Johnson & Johnson (JNJ) Given Consensus Recommendation of “Hold” by Analysts
Shares of Johnson & Johnson (NYSE:JNJ) have received a consensus recommendation of “Hold” from the twenty-two ratings firms that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $145.64.
A number of equities research analysts have issued reports on JNJ shares. Citigroup started coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective on the stock. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. UBS Group reissued a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a report on Saturday, September 30th. Piper Jaffray Companies reissued a “hold” rating and issued a $120.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 4th. Finally, Cowen set a $147.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Friday, October 6th.
Shares of Johnson & Johnson (NYSE JNJ) opened at $147.36 on Friday. The stock has a market cap of $395,890.00, a PE ratio of 25.58, a price-to-earnings-growth ratio of 2.75 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a one year low of $110.76 and a one year high of $148.32.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 19.16% and a return on equity of 20.70%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.68 earnings per share. equities analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.28%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after buying an additional 3,023,110 shares during the last quarter. BlackRock Inc. raised its holdings in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after buying an additional 4,332,612 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Johnson & Johnson by 0.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after buying an additional 130,437 shares during the last quarter. FMR LLC raised its holdings in Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after buying an additional 1,509,745 shares during the last quarter. Finally, Capital World Investors increased its position in Johnson & Johnson by 4.1% during the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after purchasing an additional 1,050,000 shares during the period. Institutional investors and hedge funds own 65.71% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.